|Bid||4.3100 x 3000|
|Ask||4.3200 x 2900|
|Day's Range||4.2000 - 4.4200|
|52 Week Range||3.8800 - 31.4500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.25|
58% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS
Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.